Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

From Bench to Application: Evaluating the In Vitro and In Vivo Efficacy of a Polyhexamethylene Biguanide and Cross-Linked Hyaluronic Acid-Based Antiseptic Solution

View through CrossRef
Background/Objectives: In the context of increasing bacterial resistance and the need for effective ophthalmic antiseptics, this study evaluates the antimicrobial efficacy of Corneial MED®, a novel ophthalmic solution containing polyhexamethylene biguanide (PHMB) and cross-linked hyaluronic acid. The study investigates the in vitro fungicidal and bactericidal properties of this solution against clinically relevant fungal and bacterial strains and its impact on conjunctival flora in vivo. Methods: The in vitro assessment included time-kill assays to determine the fungicidal or fungistatic activity against Candida albicans, Aspergillus flavus, and Aspergillus fumigatus. The bactericidal activity was evaluated against Staphylococcus aureus (methicillin-sensitive and -resistant), Staphylococcus epidermidis, Pseudomonas aeruginosa, and Escherichia coli. In vivo, 43 patients undergoing cataract surgery were treated with the solution for three days preoperatively. Results: Corneial MED® demonstrated a fungistatic effect against C. albicans and A. fumigatus, while it exhibited limited activity against A. flavus. The tested solution effectively reduced bacterial load within minutes, outperforming competitor ophthalmic solutions in activity against P. aeruginosa and E. coli. Conjunctival swabs indicated a significant reduction in bacterial load post-treatment, confirming the solution’s efficacy in reducing potential ocular pathogens. Conclusions: These findings highlight the potential of PHMB-based antiseptic solutions as a viable alternative to traditional disinfectants, particularly for preoperative prophylaxis and infection control. Further clinical trials are needed to confirm long-term safety and efficacy. The combination with cross-linked hyaluronic acid not only enhances tolerability but also extends antimicrobial action, making it a promising candidate for ophthalmic disinfection.
Title: From Bench to Application: Evaluating the In Vitro and In Vivo Efficacy of a Polyhexamethylene Biguanide and Cross-Linked Hyaluronic Acid-Based Antiseptic Solution
Description:
Background/Objectives: In the context of increasing bacterial resistance and the need for effective ophthalmic antiseptics, this study evaluates the antimicrobial efficacy of Corneial MED®, a novel ophthalmic solution containing polyhexamethylene biguanide (PHMB) and cross-linked hyaluronic acid.
The study investigates the in vitro fungicidal and bactericidal properties of this solution against clinically relevant fungal and bacterial strains and its impact on conjunctival flora in vivo.
Methods: The in vitro assessment included time-kill assays to determine the fungicidal or fungistatic activity against Candida albicans, Aspergillus flavus, and Aspergillus fumigatus.
The bactericidal activity was evaluated against Staphylococcus aureus (methicillin-sensitive and -resistant), Staphylococcus epidermidis, Pseudomonas aeruginosa, and Escherichia coli.
In vivo, 43 patients undergoing cataract surgery were treated with the solution for three days preoperatively.
Results: Corneial MED® demonstrated a fungistatic effect against C.
albicans and A.
fumigatus, while it exhibited limited activity against A.
flavus.
The tested solution effectively reduced bacterial load within minutes, outperforming competitor ophthalmic solutions in activity against P.
aeruginosa and E.
coli.
Conjunctival swabs indicated a significant reduction in bacterial load post-treatment, confirming the solution’s efficacy in reducing potential ocular pathogens.
Conclusions: These findings highlight the potential of PHMB-based antiseptic solutions as a viable alternative to traditional disinfectants, particularly for preoperative prophylaxis and infection control.
Further clinical trials are needed to confirm long-term safety and efficacy.
The combination with cross-linked hyaluronic acid not only enhances tolerability but also extends antimicrobial action, making it a promising candidate for ophthalmic disinfection.

Related Results

Pulmonary Disorders After Injections of Hyaluronic Acid Fillers
Pulmonary Disorders After Injections of Hyaluronic Acid Fillers
Hyaluronic acid is chemically a repeating glycosaminoglycan (disaccharide of D- glucuronic acid and N-acetyl-D-glucosamine), the presence of which has been established in many huma...
Polyhexamethylene biguanide hydrochloride (PHMB)-properties and application of an antiseptic agent. A narrative review
Polyhexamethylene biguanide hydrochloride (PHMB)-properties and application of an antiseptic agent. A narrative review
The prevention and management of ocular surface infections is still one of the great challenges for ophthalmologists. The spread of antimicrobial resistance makes it necessary to u...
The relationship between the naked mole-rat and hyaluronic acid, as mediated by its receptor CD44: A Mini-Review
The relationship between the naked mole-rat and hyaluronic acid, as mediated by its receptor CD44: A Mini-Review
The life expectancy of the naked mole-rat (Heterocephalus glaber) is longer than that of other rodents. In NMR cells, the hyaluronic acid concentration is at a higher level. The ex...
British Food Journal Volume 46 Issue 11 1944
British Food Journal Volume 46 Issue 11 1944
1. From the information given to the Committee by members of the trade the following conclusions were drawn : (i) Four main types of product are sold under a name commonly includin...
Efficacy of Intraarticular Hyaluronic acid and Cortico- Steroid Co-Injection versus Hyaluronic acid in Knee Osteoarthritis
Efficacy of Intraarticular Hyaluronic acid and Cortico- Steroid Co-Injection versus Hyaluronic acid in Knee Osteoarthritis
Introduction: For knee osteoarthritis, intra-articular injections of Hyaluronic acid and corticosteroid have individually shown promise, nevertheless, the rate at which symptoms im...

Back to Top